Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase IIα mRNA

被引:3
作者
Zhu, Huaiyang [1 ]
Zhou, Ying [1 ]
Wang, Qing [1 ]
Yang, Xiaobo [1 ]
Ding, Caihong [2 ]
Xiong, Yu [2 ]
机构
[1] Shandong Publ Hlth Clin Ctr, Dept Thorac Surg, Jinan 250100, Shandong, Peoples R China
[2] Shandong Publ Hlth Clin Ctr, Dept Resp Med, 12 Lieshishan East Rd, Jinan 250100, Shandong, Peoples R China
关键词
LALTOP; NSCLC; Top2; alpha; DOXORUBICIN RESISTANCE; CHALLENGES; APOPTOSIS; DESIGN;
D O I
10.1016/j.bbrc.2021.08.038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The long noncoding RNAs (lncRNAs) have been shown to actively participate in various biological processes including cancer progression. However, most lncRNAs still have undefined functions. In current work, we identified a novel lncRNA named LALTOP which displayed an oncogenic function in non-small cell lung cancer (NSCLC). LALTOP expression is increased in NSCLC tissues and cell lines. Moreover, LALTOP strongly promoted proliferation and migration of A549 and H1793 cells. RNA-RNA interaction assay showed that LALTOP bound and stabilized topoisomerase II alpha (Top2 alpha) mRNA. Positive correlation can be found between LALTOP and Top2 alpha mRNA expressions in clinical specimens. ASOs targeting LALTOP could markedly inhibit malignant phenotypes of NSCLC. Collectively, LALTOP may serve as an oncogenic lncRNA and enhances NSCLC progression. Targeting LALTOP has therapeutic potential for eradicating lung cancer cells. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 37 条
[1]   Targeting noncoding RNAs in disease [J].
Adams, Brian D. ;
Parsons, Christine ;
Walker, Lisa ;
Zhang, Wen Cai ;
Slack, Frank J. .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (03) :761-771
[2]   Immunobiology of Long Noncoding RNAs [J].
Atianand, Maninjay K. ;
Caffrey, Daniel R. ;
Fitzgerald, Katherine A. .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 35, 2017, 35 :177-198
[3]   Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy [J].
Bailly, Christian .
CHEMICAL REVIEWS, 2012, 112 (07) :3611-3640
[4]   Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1 [J].
Cao, Zhili ;
Liang, Naixin ;
Yang, Huaxia ;
Li, Shanqing .
CELL PROLIFERATION, 2017, 50 (05)
[5]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[6]   Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma [J].
Dragoj, Miodrag ;
Milosevic, Zorica ;
Bankovic, Jasna ;
Tanic, Nikola ;
Pesic, Milica ;
Stankovic, Tijana .
CELLULAR ONCOLOGY, 2017, 40 (01) :47-62
[7]   MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis [J].
Fan, Huijie ;
Yuan, Jing ;
Li, Yaqing ;
Jia, Yongxu ;
Li, Jing ;
Wang, Xiaofeng ;
Li, Xingya .
CELL DEATH & DISEASE, 2021, 12 (01)
[8]  
Ferguson DM, 2015, ANTICANCER RES, V35, P5211
[9]   Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab [J].
Fountzilas, George ;
Christodoulou, Christos ;
Bobos, Mattheos ;
Kotoula, Vassiliki ;
Eleftheraki, Anastasia G. ;
Xanthakis, Ioannis ;
Batistatou, Anna ;
Pentheroudakis, George ;
Xiros, Nikolaos ;
Papaspirou, Irene ;
Koumarianou, Anna ;
Papakostas, Pavlos ;
Bafaloukos, Dimitrios ;
Skarlos, Dimosthenis V. ;
Kalogeras, Konstantine T. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[10]   Fomivirsen - Clinical pharmacology and potential drug interactions [J].
Geary, RS ;
Henry, SP ;
Grillone, LR .
CLINICAL PHARMACOKINETICS, 2002, 41 (04) :255-260